Antares Pharma, Eli Lilly file joint patent application for needle-free injection device

By Lisa Kerner

Erie, Pa., May 30 - Antares Pharma, Inc. and Eli Lilly and Co. have filed a provisional patent application for a needle-free injection device for diabetes and obesity as a result of its joint development agreement formed in September 2003.

The filing incorporates development work focused on making products more patient friendly related to the Antares' core needle-free injector technology sold in the U.S. insulin market as the MediJector Vision, according to a company news release.

"I am pleased to report that the joint development process with Lilly has yielded some important intellectual property that both companies have sought to protect," said Jack E. Stover, president and chief executive officer of Antares, in a news release.

"We are confident that recent approvals of alternative insulin delivery systems will provide a broader awareness that our MediJector Vision and its next-generation products are available as simple and reliable alternatives to traditional needle and syringe self injections."

Antares is a specialized pharmaceutical product development company located in Exton, Pa.

Eli Lilly is an Indianapolis-based pharmaceutical products and research company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.